P.3.d.005 Paliperidone palmitate versus conventional depots in patients with schizophrenia: a 12 months study

Guillena, S.L. Romero; Diego, B.O. Plasencia García de; Galvez, A. Fernandez

doi:10.1016/s0924-977x(13)70728-4

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent 18-month study in patients with schizophrenia demonstrated significant improvements in outcomes such as remission rates and functioning with PP compared with conventional depot APs ( Romero Guillena et al, 2014 ). A year-long naturalistic study showed that PP was well tolerated ( Attard et al, 2014 ) and resulted in a significant decrease in the number of hospital admissions and the mean number of bed days per patient per year compared with previous AP treatments ( Taylor and Olofinjana, 2014 ).…”

Section: Introductionmentioning

confidence: 99%

Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics

et al. 2015

View full text Add to dashboard Cite

PALMFlexS, a prospective multicentre, open-label, 6-month, phase IIIb interventional study, explored tolerability, safety and treatment response in adults (n = 231) with non-acute but symptomatic schizophrenia switching to flexibly dosed paliperidone palmitate (PP) after unsuccessful treatment with risperidone long-acting injectable therapy (RLAT) or conventional depot antipsychotics (APs). Treatment response was measured by change in Positive and Negative Syndrome Scale (PANSS) total score from baseline (BL) to last-observation-carried-forward (LOCF) endpoint (EP). Safety and tolerability assessments included Extrapyramidal Symptom Rating Scale (ESRS) total score and treatment-emergent adverse events. Significant reductions in mean PANSS total score were observed for all groups (−7.5 to −10.6; p ⩽ 0.01 [BL to LOCF EP]). After switching to PP, more than 50% of all patients achieved ⩾20% and one-third of RLAT-treated patients even achieved ⩾50% improvement in PANSS total score. Across groups, there were significant improvements (p < 0.05) in symptom severity as measured by Clinical Global Impression-Severity (CGI-S; trend for improvement with RLAT; p = 0.0568), subjective well-being, medication satisfaction, and patient functioning with PP. PP was generally well tolerated. Clinically relevant benefits were observed in non-acute patients with schizophrenia switched from RLAT or conventional depot APs to PP.

show abstract

Section: Introductionmentioning

confidence: 99%